Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 18Melanoma 17Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3

Interventions

Cisplatin 12Etoposide 11Carboplatin 9Paclitaxel 7Ifosfamide 7Filgrastim 7Bleomycin 6Radiotherapy 5Magnetic Resonance Spectroscopy 4pegfilgrastim 3Peripheral Blood Stem Cell Transplantation 3liposomal amphotericin B 2Therapeutics 2Platinum 2Ipilimumab 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2CTLA-4 Antigen 2tremelimumab 1sodium thiosulfate 1sargramostim 1lerisetron 1ixabepilone 1etoposide phosphate 1durvalumab 1cabozantinib 1aldesleukin 1Vinblastine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Seminoma × tremelimumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡